GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00709791 | Liver | HCC | protein K11-linked ubiquitination | 24/7958 | 29/18723 | 1.04e-05 | 1.20e-04 | 24 |
GO:0048285 | Liver | HCC | organelle fission | 254/7958 | 488/18723 | 1.07e-05 | 1.23e-04 | 254 |
GO:0045786 | Liver | HCC | negative regulation of cell cycle | 204/7958 | 385/18723 | 1.84e-05 | 1.99e-04 | 204 |
GO:0045930 | Liver | HCC | negative regulation of mitotic cell cycle | 130/7958 | 235/18723 | 4.69e-05 | 4.50e-04 | 130 |
GO:2001251 | Liver | HCC | negative regulation of chromosome organization | 55/7958 | 86/18723 | 4.80e-05 | 4.60e-04 | 55 |
GO:0007091 | Liver | HCC | metaphase/anaphase transition of mitotic cell cycle | 42/7958 | 62/18723 | 5.18e-05 | 4.93e-04 | 42 |
GO:0007093 | Liver | HCC | mitotic cell cycle checkpoint | 77/7958 | 129/18723 | 6.00e-05 | 5.50e-04 | 77 |
GO:1905818 | Liver | HCC | regulation of chromosome separation | 47/7958 | 72/18723 | 7.95e-05 | 7.07e-04 | 47 |
GO:0051983 | Liver | HCC | regulation of chromosome segregation | 57/7958 | 91/18723 | 8.35e-05 | 7.36e-04 | 57 |
GO:0010965 | Liver | HCC | regulation of mitotic sister chromatid separation | 43/7958 | 65/18723 | 9.99e-05 | 8.60e-04 | 43 |
GO:0051306 | Liver | HCC | mitotic sister chromatid separation | 44/7958 | 67/18723 | 1.08e-04 | 9.22e-04 | 44 |
GO:0030071 | Liver | HCC | regulation of mitotic metaphase/anaphase transition | 40/7958 | 60/18723 | 1.34e-04 | 1.10e-03 | 40 |
GO:0033045 | Liver | HCC | regulation of sister chromatid segregation | 46/7958 | 72/18723 | 2.02e-04 | 1.56e-03 | 46 |
GO:0044784 | Liver | HCC | metaphase/anaphase transition of cell cycle | 42/7958 | 65/18723 | 2.63e-04 | 1.94e-03 | 42 |
GO:1901988 | Liver | HCC | negative regulation of cell cycle phase transition | 132/7958 | 249/18723 | 4.97e-04 | 3.25e-03 | 132 |
GO:0033047 | Liver | HCC | regulation of mitotic sister chromatid segregation | 31/7958 | 46/18723 | 5.67e-04 | 3.61e-03 | 31 |
GO:0045839 | Liver | HCC | negative regulation of mitotic nuclear division | 32/7958 | 48/18723 | 6.21e-04 | 3.86e-03 | 32 |
GO:1902099 | Liver | HCC | regulation of metaphase/anaphase transition of cell cycle | 40/7958 | 63/18723 | 6.22e-04 | 3.86e-03 | 40 |
GO:0000280 | Liver | HCC | nuclear division | 220/7958 | 439/18723 | 6.90e-04 | 4.25e-03 | 220 |
GO:00900683 | Liver | HCC | positive regulation of cell cycle process | 125/7958 | 236/18723 | 7.21e-04 | 4.40e-03 | 125 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa041146 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
hsa0411411 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
hsa0412041 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0516622 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0412051 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa0516632 | Liver | HCC | Human T-cell leukemia virus 1 infection | 139/4020 | 222/8465 | 3.17e-06 | 2.79e-05 | 1.55e-05 | 139 |
hsa0516630 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
hsa05166113 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANAPC1 | SNV | Missense_Mutation | | c.2765N>T | p.Ser922Phe | p.S922F | Q9H1A4 | protein_coding | tolerated(0.07) | benign(0.347) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ANAPC1 | SNV | Missense_Mutation | | c.1549N>A | p.Pro517Thr | p.P517T | Q9H1A4 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | | c.655N>A | p.Glu219Lys | p.E219K | Q9H1A4 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ANAPC1 | SNV | Missense_Mutation | | c.415N>C | p.Glu139Gln | p.E139Q | Q9H1A4 | protein_coding | tolerated(0.29) | benign(0.075) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ANAPC1 | SNV | Missense_Mutation | novel | c.5782N>G | p.Leu1928Val | p.L1928V | Q9H1A4 | protein_coding | tolerated(0.12) | possibly_damaging(0.899) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | | c.5683N>T | p.Pro1895Ser | p.P1895S | Q9H1A4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | novel | c.3620N>A | p.Gly1207Glu | p.G1207E | Q9H1A4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BH-A0AZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
ANAPC1 | SNV | Missense_Mutation | | c.2563N>A | p.Glu855Lys | p.E855K | Q9H1A4 | protein_coding | tolerated(0.76) | benign(0.04) | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
ANAPC1 | SNV | Missense_Mutation | novel | c.4217T>C | p.Leu1406Pro | p.L1406P | Q9H1A4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-BH-A0HA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ANAPC1 | SNV | Missense_Mutation | novel | c.2050N>C | p.Glu684Gln | p.E684Q | Q9H1A4 | protein_coding | tolerated(0.07) | benign(0.149) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |